Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2011. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 1,200,000 ordinary shares of 25 pence each.
- Purchase Date: August 1, 2011.
- Price Range: Highest price paid was 1,375 pence per share; lowest price paid was 1,348 pence per share.
- Treasury Holdings (Settled): 495,796,816 shares (8.85% of total issued share capital).
- Treasury Holdings (Including Unsettled): 498,721,816 shares (9.76% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,109,244,945 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 1,200,000 shares on August 1, 2011. This transaction increased the proportion of shares held in Treasury to 8.85% of total issued share capital. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. The only operational note is the Company's intention to hold the repurchased shares in Treasury. The document clarifies that the number of shares in issue (excluding treasury shares) represents the total voting rights and serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (495,796,816 settled) against the company's latest capitalization table.
- Confirm the total issued share capital excluding treasury shares (5,109,244,945) for voting rights calculations.
- Review the price paid per share (1,348 to 1,375 pence) to assess the cost of capital return relative to market prices on August 1, 2011.
- Note that this filing does not contain financial results; refer to the most recent Form 20-F or quarterly earnings release for revenue and profit data.